JUSTIFICATION OF THE STUDY OF THE ACTIVE INGREDIENTS OF A CREAM FOR THE TREATMENT OF ALLERGIC DERMATITIS
DOI:
https://doi.org/10.11603/2312-0967.2023.1.13911Keywords:
cream, dermatitis, salix alba, zincAbstract
The aim of the work. Experimental study of the active substances of the dermatitis cream. "Pirusalix" for the treatment of allergies.
Materials and Methods. The study was performed on outbred sexually mature rats (males and females) weighing 150–180 g and divided into 5 groups. The effect of the researched drugs was studied under the conditions of a therapeutic and preventive regime. Inflammation was caused by subplantar injection of 1 % carrageenan solution and 2 % zymosan solution into the rear right paw of rats. Since the cream is a product for external use, it was necessary to study its possible toxic effect at a single dermal application.
Results and Discussion. It has been experimentally proven that among the active substances that make up the cream "Pirisalix" the most pronounced anti- inflammatory activity is the extract of the bark of the salix alba on the model carrageenin- induced inflammation in rats. In the zymosan inflammation model, two active substances salix alba and zinc showed an active effect. salix alba bark contains the maximum amount of salicylates, which reduce the effect of inflammatory mediators on vascular permeability and have anti- inflammatory properties. analgesic properties, which corresponds to the data of the literature. The obtained results indicate that the cream "Psorikap" affects the inhibition of inflammatory mediators of leukotrienes, which are observed against the background of allergic reactions. It was established that the researched cream "Pirisalix" belongs to the IV class of toxicity of low- toxic substances.
Conclusions. Based on the anti-inflammatory activity data, justified the expediency of the composition of salix alba bark extract and zinc as active ingredients of Pirisalix cream for the treatment of dermatitis of allergic etiology.
References
Mojina T.L. [Atopic dermatitis through the lens of impaired lymphatic drainage: opportunities to improve the effectiveness and safety of treatment]. Med hazeta “Zdorovya Ukraine 21 storichia”. 2022;13(530). Ukrainin.
Stingeni L, Belloni Fortina A, Baiardini I, Hansel K, Moretti D, Cipriani F. Atopic dermatitis and patient perspectives: insights of bullying at school and career discrimination at work. J Asthma Allergy. 2021;14(919): 28. DOI: https://doi.org/10.2147/JAA.S317009
Reznichenko NYu. [Allergic contact dermatitis: current ideas about treatment based on a review of the scientific literature]. Aktualni pytan farmats i med nauky i praktyky. 2013;3: 69-72. http://nbuv.gov.ua/UJRN/apfimntp_2013_3_22. Ukrainin.
Luger T, Romero WA, Gruben D. Clinical and humanistic burden of atopic dermatitis in Europe: Analyses of the National Health and Wellness Survey. Dermatol. Ther. (Heidelb). 2022;12: 949-69. https://doi.org/10.1007/s13555-022-00700-6 DOI: https://doi.org/10.1007/s13555-022-00700-6
Bardova KO. [An innovative approach to the diagnosis of allergic dermatoses and personalized skin care]. Med hazeta “Zdorovia Ukrainy 21 storichia”. 2019. № 2 (447).
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1): 1. https://doi.org/10.1038/s41572-018-0001-z DOI: https://doi.org/10.1038/s41572-018-0001-z
Barbarot S, Auziere S, Gadkari A. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6): 1284-93. DOI: 10.1111/all.13401 DOI: https://doi.org/10.1111/all.13401
State Pharmacopoeia of Ukraine. 2nd edition. [State Pharmacopoeia of Ukraine. 2nd edition] Kharkiv. State Enterprise “Ukrainskyi nauk farmakop tsentr yakosti likarskykh zasobiv”. 2014. Ukrainian.
Kogan BG, Verba YeA. New European approaches in the therapy of resistant forms of allergic dermatoses. Ukr zhurn dermatol, venerol, kosmetol. 2013;1(48): 137-143.
https://www.pharmencyclopedia.com.ua/article/475/salicilati
https://www.pharmencyclopedia.com.ua/article/2997/glicerin
https://www.pharmencyclopedia.com.ua/article/980/propilenglikol
https://heess-ukr.ub.ua/ru/goods/view/21652375/all/peg-100-stearat-peg-100-stearate/
Stefanov OV. Preclinical studies of drugs: guidelines. Kyiv: Avitsenna. 2001. Ukrainian.
Prozorovskii VB. [Tabular express method of determining the average effective impact on biological objects]. Toksikol visn. 1998;1: 28-32. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
